Analyst Price Target is $108.50
▲ +18.49% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $108.50, with a high forecast of $112.00 and a low forecast of $105.00. The average price target represents a 18.49% upside from the last price of $91.57.
Current Consensus is
The current consensus among 11 investment analysts is to hold stock in Novartis. This Hold consensus rating has held steady for over two years.
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.